An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DermTech (NASDAQ: DMTK) is participating in the 2023 American Academy of Dermatology Annual Meeting from March 17-21 in New Orleans. The company will present four new posters related to basal cell carcinoma diagnostics and melanoma detection. Key presentations include non-invasive RNA detection and performance of the pigmented lesion assay on higher Fitzpatrick Skin Types. DermTech will showcase its innovative melanoma test, which boasts a negative predictive value over 99%, at booth #2839. The company also commits to donating $100 to AAD Skin Cancer Awareness for each badge scanned during the event. DermTech aims to enhance awareness and access to melanoma screening solutions.
Positive
None.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that it is participating in the 2023 American Academy of Dermatology (AAD) Annual Meeting, which will take place on March 17-21 in New Orleans.
DermTech will present four new posters focused on topics including the efforts in development of a basal cell carcinoma diagnostic gene signature and evaluation of the DermTech Melanoma Test (DMT) in higher Fitzpatrick Skin Types. The posters are titled:
Non-invasive detection of RNAs associated with basal cell carcinoma. Bahrami-Samani et al.
Pigmented lesion assay performance in Fitzpatrick Phototypes IV-VI. Rock et al.
Fitzpatrick Skin Phototypes: More than just skin deep. Xayavong et al.
An analysis of the average age of skin cancer reported by subjects with Fitzpatrick Phototypes I through VI. Herron et al.
DermTech will also be highlighting the innovative DMT at its booth (#2839). Designed to enhance melanoma detection, the test uses non-invasive Smart Stickers™ to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. With a negative predive value of over 99%, the test can rule out melanoma with high probability. At DermTech’s booth, attendees can gain hands-on experience with the Smart Stickers and learn more about the clinical data and science behind the test and how to best implement the DMT into a dermatology practice.
“We are excited to build on the momentum from last year's meeting and solidify DermTech as a major player in dermatology,” said Todd Wood, chief commercial officer at DermTech. “Presenting new data and connecting with professionals from across the country is a key component of raising awareness and expanding access to our test. Our ultimate goal is to help end deaths from melanoma.”
DermTech is participating in the AAD’s Cause Supporter program and will donate $100 to AAD Skin Cancer Awareness for every badge scanned at its booth (see aad.org/support-cause for AAD terms and conditions). DermTech is a proud AAD Annual Meeting Cause Supporter for the second year in a row, supporting AAD skin cancer awareness and prevention initiatives.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” "outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency, implications and interpretations of any study results, expectations regarding reimbursement or cash collection patterns from Medicare from commercial payors and related billing practices or number of covered lives, and DermTech’s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and commercial payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
What is DermTech showcasing at the 2023 AAD Annual Meeting?
DermTech will present four new posters focusing on basal cell carcinoma diagnostics and melanoma detection, alongside showcasing its melanoma test at booth #2839.
When will DermTech participate in the AAD Annual Meeting?
DermTech is participating in the 2023 AAD Annual Meeting from March 17-21 in New Orleans.
What is the negative predictive value of DermTech's melanoma test?
DermTech's melanoma test has a negative predictive value of over 99%, allowing for high confidence in ruling out melanoma.
How much will DermTech donate for each badge scanned at its booth?
DermTech will donate $100 to AAD Skin Cancer Awareness for every badge scanned at its booth during the AAD Annual Meeting.
Where can I find more information about DermTech?
More information about DermTech can be found on their website at https://dermtech.com/
